Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual MeetingBusiness Wire • 06/06/22
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket' Trial of Neratinib at the ASCO 2022 Annual MeetingBusiness Wire • 06/04/22
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual MeetingBusiness Wire • 05/26/22
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach On Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Puma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/28/22
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual MeetingBusiness Wire • 04/27/22
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial ResultsBusiness Wire • 04/21/22
Puma Biotechnology to Participate in Breast Cancer Panel at Cowen's Annual Health Care ConferenceBusiness Wire • 03/07/22
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/04/22
Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/17/22
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 02/16/22
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast CancerBusiness Wire • 01/12/22
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual MeetingBusiness Wire • 12/10/21
Do Options Traders Know Something About Puma (PBYI) Stock We Don't?Zacks Investment Research • 12/03/21
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)Business Wire • 11/23/21